Calquence (acalabrutinib) — CareFirst (Caremark)
Chronic lymphocytic leukemia (CLL)
Initial criteria
- Authorization may be granted for treatment as a single agent or in combination with obinutuzumab.
Reauthorization criteria
- Authorization may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months